A First-In-Human Trial of pTTL in Advanced Colorectal Cancer

This is an open-label, non-randomised FIH trial investigating the safety and tolerability of a novel ATMP, pTTL, composed of autologous tumour-draining lymph node-derived T cells stimulated in vitro with personalised cancer neoantigens. The neoantigens are selected through a process starting with next generation sequencing (NGS) of tumour material from the patient followed by selection of neoantigenic mutations using an in-house software, PIOR®. Selected neoantigen epitopes are expressed as recombinant proteins, NAG, and used to stimulate T cells to promote neoantigen-specific T cell expansio

Trial Details

NCT ID
NCT05908643
Phase
PHASE1 / PHASE2
Sponsor
Neogap Therapeutics AB
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • pTTL
Locations (sample)
  • Stockholm, Stockholm County, Sweden|59.32938,18.06871
  • Västerås, Västerås, Sweden|59.61617,16.55276

Key Eligibility Criteria

  • Signed informed consent.
  • Adult (age ≥18 years).
  • Histological or cytological confirmation of CRC.
  • Verified metastatic disease (stage IV classification) and have received all possible standard of care therapies, OR further standard of care therap…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →